EMERGENT BIOSOLUTIONS INC. Proceeds from (Repayments of) Restricted Cash, Financing Activities
EMERGENT BIOSOLUTIONS INC. (EBS) reported Proceeds from (Repayments of) Restricted Cash, Financing Activities of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities · last filed 2020-02-25
- EMERGENT BIOSOLUTIONS INC. proceeds from (repayments of) restricted cash, financing activities for the quarter ending 2018-12-31 was $1.10M, a 2458.14% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. proceeds from (repayments of) restricted cash, financing activities for the quarter ending 2017-12-31 was $43.00K.
- EMERGENT BIOSOLUTIONS INC. proceeds from (repayments of) restricted cash, financing activities for the quarter ending 2016-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from (repayments of) restricted cash, financing activities for the quarter ending 2013-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from (repayments of) restricted cash, financing activities for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- EMERGENT BIOSOLUTIONS INC. proceeds from (repayments of) restricted cash, financing activities for fiscal 2018 was $1.10M.
- EMERGENT BIOSOLUTIONS INC. proceeds from (repayments of) restricted cash, financing activities for fiscal 2017 was -$1.00M.
- EMERGENT BIOSOLUTIONS INC. proceeds from (repayments of) restricted cash, financing activities for fiscal 2016 was $0.00.
| Period end | Proceeds from (Repayments of) Restricted Cash, Financing Activities 3 month | Proceeds from (Repayments of) Restricted Cash, Financing Activities 6 month | Proceeds from (Repayments of) Restricted Cash, Financing Activities 9 month | Proceeds from (Repayments of) Restricted Cash, Financing Activities 12 month | Proceeds from (Repayments of) Restricted Cash, Financing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-25 | ||||
| 2018-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $1.10M 10-K · filed 2020-02-25 | |||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-02 | ||||
| 2017-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$1.00M 10-K · filed 2020-02-25 | -$1.04M 10-K · filed 2018-02-23 | ||
| 2017-09-30 | -$1.04M 10-Q · filed 2018-11-02 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $0.00 10-K · filed 2019-02-22 | |||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-03 | ||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-23 | ||||
| 2014-12-31 | $0.00 10-K · filed 2015-03-09 | ||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $0.00 derived: sum of 2 quarters · filed 2015-03-09 | $0.00 derived: sum of 3 quarters · filed 2015-03-09 | $0.00 10-K · filed 2015-03-09 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $0.00 derived: sum of 2 quarters · filed 2013-11-08 | $0.00 10-Q · filed 2013-11-08 | $0.00 derived: sum of 4 quarters · filed 2015-03-09 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $0.00 10-Q · filed 2013-08-06 | $0.00 derived: sum of 3 quarters · filed 2015-03-09 | $0.00 derived: sum of 4 quarters · filed 2015-03-09 | |
| 2013-03-31 | $0.00 10-Q · filed 2013-05-03 | $0.00 derived: sum of 2 quarters · filed 2015-03-09 | $0.00 derived: sum of 3 quarters · filed 2015-03-09 | $0.00 derived: sum of 4 quarters · filed 2015-03-09 | |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $0.00 derived: sum of 2 quarters · filed 2015-03-09 | $0.00 derived: sum of 3 quarters · filed 2015-03-09 | $220.00K 10-K · filed 2015-03-09 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $0.00 derived: sum of 2 quarters · filed 2013-11-08 | $220.00K 10-Q · filed 2013-11-08 | $217.00K derived: sum of 4 quarters · filed 2014-03-10 | |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $220.00K 10-Q · filed 2013-08-06 | $217.00K derived: sum of 3 quarters · filed 2014-03-10 | $217.00K derived: sum of 4 quarters · filed 2014-03-10 | |
| 2012-03-31 | $220.00K 10-Q · filed 2013-05-03 | $217.00K derived: sum of 2 quarters · filed 2014-03-10 | $217.00K derived: sum of 3 quarters · filed 2014-03-10 | $217.00K derived: sum of 4 quarters · filed 2014-03-10 | |
| 2011-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | -$3.00K derived: sum of 2 quarters · filed 2014-03-10 | -$3.00K derived: sum of 3 quarters · filed 2014-03-10 | -$3.00K 10-K · filed 2014-03-10 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $0.00 derived: sum of 2 quarters · filed 2012-11-01 | $0.00 10-Q · filed 2012-11-01 | ||
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $0.00 10-Q · filed 2012-08-03 | |||
| 2011-03-31 | $0.00 10-Q · filed 2012-05-04 | ||||
| 2010-12-31 | -$2.00K 10-K · filed 2013-03-08 | ||||
| 2009-12-31 | -$7.00K 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |